Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
48 USD | -2.87% | +1.69% | +34.91% |
May. 10 | Crinetics Pharmaceuticals Insider Sold Shares Worth $5,307,931, According to a Recent SEC Filing | MT |
May. 09 | Crinetics Pharmaceuticals Q1 Net Loss Widens | MT |
Financials (USD)
Sales 2024 * | 2.63M | Sales 2025 * | 20.16M | Capitalization | 3.78B |
---|---|---|---|---|---|
Net income 2024 * | -268M | Net income 2025 * | -293M | EV / Sales 2024 * | 1,159 x |
Net cash position 2024 * | 736M | Net cash position 2025 * | 531M | EV / Sales 2025 * | 161 x |
P/E ratio 2024 * |
-13.4
x | P/E ratio 2025 * |
-12.5
x | Employees | 290 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.87% |
Latest transcript on Crinetics Pharmaceuticals, Inc.
1 day | -2.87% | ||
1 week | +1.69% | ||
Current month | +9.54% | ||
1 month | -0.06% | ||
3 months | +21.64% | ||
6 months | +78.24% | ||
Current year | +34.91% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Betz
FOU | Founder | 58 | 07-12-31 |
Scott Struthers
FOU | Founder | 62 | 07-12-31 |
Marc Wilson
DFI | Director of Finance/CFO | 45 | 17-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wendell Wierenga
CHM | Chairman | 76 | 15-09-30 |
Matthew Fust
BRD | Director/Board Member | 59 | 18-01-31 |
Director/Board Member | 71 | 20-09-02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.09% | 0 M€ | 0.00% | - | |
0.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 48 | -2.87% | 988,384 |
24-05-09 | 49.42 | -2.89% | 841,390 |
24-05-08 | 50.89 | +6.78% | 1,927,255 |
24-05-07 | 47.66 | +2.49% | 677,927 |
24-05-06 | 46.5 | -1.48% | 561,205 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.91% | 3.78B | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- CRNX Stock